ing metal springs: estimation reveals the proportionality between force and extension, Hooke's law; P tells you, "When you pull on it, it gets longer" 4 . Medical research has led the way in adopting estimation statistics. Using the effect size in the clinical research context rightfully places the focus on the magnitude of a treatment's benefit, a perspective that has greatly advanced clinical decision making. For basic research, adopting effect sizes would better facilitate quantitative comparisons and models (such as Hooke's law). Importantly, thinking about effect sizes during data interpretation encourages an analyst to have greater awareness of the metrics being used and how they relate to the natural processes under study.
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The second key benefit of estimation statistics is that it allows for the synthesis of data from published sources by means of systematic literature review and meta-analysis. Meta-analysis is a way to average effect sizes from different studies, which produces a more precise overall estimate (that is, a narrower confidence interval). In medical research, meta-analytic studies of randomized controlled clinical trials are considered the strongest form of medical evidence; they are used to reconcile discordant results, produce precise estimates of treatment effects, identify knowledge gaps, guide clinical practice and inform further investigation. Meta-analyses are published in numerous medical journals as a quantitative alternative to the conventional 'he said/she said' narrative review. Meta-analytic studies are now also being used in preclinical research; for example, a recent study showed that the animal-model literature on stroke overstates efficacy 5 .
Estimation statistics' third important benefit is its use of model construction to quantify trends in heterogeneous primary or published data. Models can be basic or more advanced, such as multivariate meta-regression, a method that accounts for sources of experimental heterogeneity in complex data. Like clinical data, basic research results are well suited to the use of multivariate models to analyze both primary and pooled published data from complex experimental designs. When the data have high integrity, such models can resolve discordance and misinterpretation caused by significance tests 6 .
The use of estimation statistics remains rare in basic research. We suggest that as researchers become increasingly aware of the limitations of significance testing, they should use estimation in its place.
The mutation significance cutoff: genelevel thresholds for variant predictions
To the Editor: Next-generation sequencing (NGS) identifies about 20,000 variants per exome, of which only a few may underlie genetic diseases. Variant-level methods such as PolyPhen-2 (polymorphism phenotyping version 2), SIFT (sorting intolerant from tolerant) and CADD (combined annotation-dependent depletion) attempt to predict whether a given variant is benign or deleterious [1] [2] [3] . These methods are commonly interpreted in a binary manner as a means of filtering out benign variants from NGS data, with a single significance cutoff value across all genes. CADD developers propose (but do not recommend for categorical usage) a fixed cutoff value between 10 and 20 on a scale of 1-99, with 99 being the most deleterious. Gene-level methods, including RVIS (residual variation intolerance score, which applies combined fixed geneand variant-level cutoffs), de novo excess and GDI (gene damage index), are also useful [4] [5] [6] . However, a uniform cutoff is unlikely to be accurate genome-wide (see Supplementary Note).
Here we describe the mutation significance cutoff (MSC), a quantitative approach that provides gene-level and gene-specific phenotypic impact cutoff values to improve the use of existing variant-level methods, and a public server for utilizing it (http://lab.rockefeller.edu/casanova/MSC). We first showed that with fixed cutoffs CADD outperformed PolyPhen-2 and SIFT (Supplementary Fig. 1a) . We found that 40.84% of Human Gene Mutation Database (HGMD) 7 curated disease-associated mutations were not missense (but rather nonsense, frameshift, regulatory, etc.) (Fig. 1a) , contributing to low true positive predictions with PolyPhen-2 and SIFT. The 95% confidence interval (CI) of CADD scores for disease-associated mutations of a given HGMD gene overlapped, on average, with only 37.63% (41.89% median) of the 95% mutation CIs of all other HGMD genes (Fig. 1b) . The CADD scores of private disease-associated mutations were significantly higher than those of non-private disease-associated mutations (P < 10 -300 , Supplementary Fig. 1b) , resulting in lower overall impact prediction scores when the allele frequency of a mutation was considered (Supplementary Fig. 2) .
We defined the MSC of a gene as the lower limit of the CI (90%, 95% or 99%) for the CADD, PolyPhen-2 or SIFT score of all its high-quality mutations described as pathogenic in HGMD or the ClinVar database 8 (see Supplementary Methods). The MSC values (Fig. 1c, Supplementary Tables 1-9 ) varied considerably from gene to gene. We estimated the MSC values of the remaining protein-coding genes by an extrapolation from their rare nonsynonymous 1,000 Genomes Project 9 alleles and validated these values by bootstrapping simulations (see Supplementary Methods, Supplementary Fig. 3, Supplementary Tables 1-9 for MSC based on CADD, PolyPhen-2 and SIFT with 90%, 95% and 99% CIs, respectively, and Supplementary Fig. 4a for 95% CI MSC scores).
We found significant correlations between MSC and GDI values (P < 10 -5 , Supplementary Fig. 4b ) 6 and between MSC and purifying selection values (P < 10 -5 , Supplementary Fig. 4c) . Low-MSC genes were associated with immune system pathways, whereas genes with high MSC values were enriched in ribosomal function (Supplementary Figs. 4d,e and Supplementary Table 10) . MSC showed significantly better performance in distinguishing benign from deleterious alleles compared with CADD scores 
